In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements ...

The US Food and Drug Administration (FDA) has granted approval for Roche's Gazyva/ Gazyvaro (obinutuzumab) to treat adult ...

A new study has found that women with systemic lupus erythematosus who have problems with memory and thinking (mild cognitive impairment, or MCI) exhibit morphological brain changes.

With the lupus treatment landscape poised for a shake-up, Roche is hitting t | Early Monday, Roche announced that the FDA ...

The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving standard therapy, ...

The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for adults with lupus nephritis (LN), also known as lupus-related kidney disease ...

Obinutuzumab (Gazyva) is the first drug to be approved for lupus nephritis since the approvals of belimumab (Benlysta) in 2020 and voclosporin (Lupkynis) in 2021.

The Food and Drug Administration (FDA) has approved Gazyva ® (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.

The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of ...

The FDA has approved Genentech’s Gazyva (obinutuzumab) for the treatment of lupus nephritis in adults, according to a news release published today. Gazyva is the first and only anti-CD20 monoclonal ...